June MIMS update

Some of the recent changes to the medicines landscape, with new products, indications, contraindications and presentations  New Products Lazertinib (as mesilate monohydrate) (Lazcluze) is a third generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that selectively inhibits both primary activating EGFR mutations (exon 19 deletions and exon 21 L858R substitution mutations) and the EGFR